Taro rejects Sun Pharma offer

Thursday, July 19, 2012 02:25 PM

The special committee of the board of directors of Taro Pharmaceutical Industries unanimously rejected the Oct. 18, 2011, unsolicited, non-binding offer from Sun Pharmaceutical Industries—to purchase all of the issued and outstanding shares of Taro not currently held by Sun Pharma for $24.50 per share—as inadequate and not in the best interests of Taro's minority shareholders.

The special committee reached its conclusion after careful consideration, including a thorough review of Taro's business and prospects with its independent financial advisor legal counsel.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs